A study found that pregnancy exposure to the fungicide vinclozolin triggered disease patterns in rats that persisted for 20 generations. The findings point to epigenetic changes in germline cells and potential uses for epigenetic biomarkers in preventative diagnostics.
Three interconnected life sciences infrastructure markets are experiencing significant growth driven by precision medicine adoption, increasing clinical trial activity, and advances in genomic diagnostics through 2035.
Protein biomarkers and self-sampling methods are transforming drug development and occupational health surveillance, enabling more efficient clinical trials, improved target selection, and minimally invasive continuous monitoring.
The global epigenetics drugs and diagnostic technologies market is projected to reach USD 79.03 billion by 2035, while the genomics in cancer care market is expected to hit USD 108.69 billion, driven by precision medicine advances and AI integration.
